Glenmark Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
GLENMARK
Pharmaceuticals
Share Price NSE
₹2173.50
▲
59.40 (2.81%)
Share Price BSE
₹2174.35
▲
61.00 (2.89%)
Track Glenmark Pharmaceuticals share price live with TickJournal's free stock screener.
Analyze Glenmark Pharmaceuticals share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Glenmark Pharmaceuticals Market Cap
₹59,030.77 Cr.
GLENMARK P/E Ratio (TTM)
55.65
Glenmark Pharmaceuticals P/B Ratio
6.19
EPS (TTM)
₹37.11
Dividend Yield
0.12%
Debt to Equity
0.22
GLENMARK 52 Week High
₹2272.70
Glenmark Pharmaceuticals 52 Week Low
₹1342.40
Operating Margin
5.00%
Profit Margin
0.12%
GLENMARK Revenue (TTM)
₹3,232.00
EBITDA
₹164.00
Net Income
₹4.00
Total Assets
₹16,050.00
Total Equity
₹8,849.00
Glenmark Pharmaceuticals Share Price History - Stock Screener Chart
Screen GLENMARK historical share price movements with interactive charts. Analyze price trends and patterns.
Glenmark Pharmaceuticals Company Profile - Fundamental Screener
Screen Glenmark Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GLENMARK shares.
Glenmark Pharmaceuticals Ltd is an Indian research-led global pharmaceutical company founded in 1977. It focuses on developing and manufacturing branded generics, generic drugs, and over-the-counter products in therapeutic areas like respiratory, dermatology, and oncology. The company has a significant presence in emerging markets and operates 14 manufacturing facilities across several...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Glenn Saldanha
ISIN
INE935A01035
Website
https://www.glenmarkpharma.com
Glenmark Pharmaceuticals Balance Sheet Screener
Screen GLENMARK balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16,050 | 14,359 | 19,372 | 17,083 | 15,604 | 14,685 | 13,296 | 12,595 | 11,764 | 10,193 |
| Current Assets | 9,296 | 7,428 | 9,874 | 8,282 | 7,360 | 6,804 | 6,697 | 6,989 | 6,875 | 5,904 |
| Fixed Assets | 4,487 | 4,210 | 6,202 | 5,887 | 5,129 | 5,029 | 3,670 | 3,030 | 2,755 | 2,594 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,234 | 693 | 4,487 | 2,956 | 4,338 | 4,489 | 3,670 | 4,144 | 4,569 | 2,564 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 8,849 | 7,848 | 9,839 | 9,438 | 7,064 | 6,070 | 5,605 | 5,163 | 4,492 | 3,629 |
| Share Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves & Surplus | 8,821 | 7,820 | 9,446 | 9,058 | 7,036 | 6,042 | 5,577 | 5,135 | 4,464 | 3,601 |
Glenmark Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Glenmark Pharmaceuticals income statement and profit fundamentals.
Analyze GLENMARK quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Glenmark Pharmaceuticals share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,232 | 3,086 | 6,204 | 3,933 | 3,814 | 3,255 | 3,440 | 3,333 | 3,062 | 3,018 | 3,281 | 2,625 | 3,068 | 2,903 | 3,069 |
| Expenses | 3,068 | 3,007 | 5,072 | 3,215 | 3,005 | 2,656 | 2,832 | 2,787 | 3,402 | 2,651 | 3,071 | 2,792 | 2,638 | 2,346 | 2,539 |
| EBITDA | 164 | 79 | 1,132 | 717 | 808 | 599 | 608 | 546 | -340 | 367 | 211 | -168 | 430 | 558 | 530 |
| Operating Profit % | 5.00% | 2.00% | 16.00% | 17.00% | 0.00% | 18.00% | 17.00% | 16.00% | -15.00% | 12.00% | 3.00% | -13.00% | 11.00% | 14.00% | 15.00% |
| Depreciation | 125 | 130 | 141 | 154 | 151 | 118 | 120 | 123 | 135 | 142 | 141 | 147 | 132 | 147 | 146 |
| Interest | 67 | 58 | 67 | 41 | 149 | 40 | 49 | 52 | 109 | 112 | 122 | 134 | 87 | 60 | 83 |
| Profit Before Tax | 8 | 96 | 967 | 534 | 555 | 462 | 473 | 456 | -542 | 151 | -6 | -403 | 270 | 408 | 337 |
| Tax | 4 | 49 | 357 | 131 | 1,770 | 122 | 118 | 108 | -139 | -22 | 56 | -72 | 97 | 197 | 58 |
| Net Profit | 4 | 47 | 610 | 403 | -1,214 | 340 | 355 | 348 | -403 | 173 | -62 | -331 | 173 | 211 | 279 |
| EPS | 0.16 | 1.66 | 21.63 | 14.29 | -43.17 | 12.06 | 12.55 | 12.33 | -15.18 | 5.31 | -2.90 | -12.45 | 5.51 | 6.82 | 9.23 |
Glenmark Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GLENMARK cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -828 | -265 | 625 | 1,109 | 1,131 | 1,392 | 1,324 | 1,648 | 657 | 345 |
| Investing Activities | 58 | 4,387 | -515 | -316 | -662 | -774 | -883 | -1,003 | -1,001 | -950 |
| Financing Activities | 787 | -3,906 | -78 | -521 | -442 | -445 | -739 | -469 | 543 | 699 |
| Net Cash Flow | 17 | 215 | 33 | 272 | 28 | 174 | -297 | 177 | 199 | 93 |
Glenmark Pharmaceuticals Shareholding Pattern Screener
See Glenmark Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Glenmark Pharmaceuticals promoter holding and ownership changes for GLENMARK on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 46.65% | 46.65% | 46.65% | 46.65% | 46.64% | 46.65% | 46.65% | 46.65% |
| FII Holding | 23.16% | 20.62% | 20.73% | 19.20% | 21.38% | 20.98% | 23.05% | 23.51% |
| DII Holding | 14.60% | 17.64% | 18.61% | 20.09% | 13.36% | 13.92% | 13.21% | 13.85% |
| Govt Holding | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public Holding | 12.32% | 11.69% | 10.81% | 10.77% | 14.83% | 14.58% | 13.61% | 12.65% |
| Other Holding | 3.24% | 3.37% | 3.16% | 3.26% | 3.75% | 3.83% | 3.45% | 3.31% |
| Shareholder Count | 192,724 | 190,210 | 198,789 | 201,584 | 199,451 | 192,630 | 193,949 | 195,059 |
Glenmark Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Glenmark Pharmaceuticals dividend history with payout and yield data.
View Glenmark Pharmaceuticals dividend details including ex-dates and amounts for GLENMARK stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹2.50 | 0.12% |
| 2024-March | ₹2.50 | 0.16% |
| 2023-March | ₹2.50 | 0.26% |
| 2022-March | ₹2.50 | 0.56% |
| 2021-March | ₹2.50 | 0.57% |
| 2020-March | ₹2.50 | 0.54% |
| 2019-March | ₹2.00 | 0.97% |
| 2018-March | ₹2.00 | 0.31% |
| 2017-March | ₹2.00 | 0.38% |
Glenmark Pharmaceuticals Stock Index Membership
See which indices include Glenmark Pharmaceuticals stock.
Check GLENMARK index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEMOI
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 200
NIFTY 500
NIFTY ALPHA 50
NIFTY HEALTHCARE
NIFTY LARGEMID250
NIFTY MIDCAP 100
NIFTY MIDCAP 150
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY TOTAL MKT
NIFTY200 ALPHA 30
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 SHARIAH
Glenmark Pharmaceuticals Market Events Screener - Corporate Actions
Get Glenmark Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Glenmark Pharmaceuticals stock events that may affect GLENMARK share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 2.50 /share | 49.01% | ||
| Dividend | ₹ 2.50 /share | -1.14% | ||
| Dividend | ₹ 2.50 /share | 40.83% | ||
| Annual General Meeting | NA | 3.71% | ||
| Dividend | ₹ 2.50 /share | 69.51% | ||
| Annual General Meeting | NA | -0.47% | ||
| Dividend | ₹ 2.50 /share | -13.54% | ||
| Annual General Meeting | NA | 4.61% | ||
| 2026-01-30 | 2026-01-30 | Quarterly Result Announcement | NA | -0.69% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -0.74% |
| 2025-10-03 | 2025-10-03 | Dividend | ₹ 2.50 /share | -3.56% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -1.86% |
| 2025-05-23 | 2025-05-23 | Quarterly Result Announcement | NA | 2.35% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -1.75% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -8.04% |
Glenmark Pharmaceuticals Competitors Screener - Peer Comparison
Screen GLENMARK competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Glenmark Pharmaceuticals Company Announcements - News Screener
Screen GLENMARK latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-06 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Action/ Inspection | - |
| 2026-04-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-21 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-20 | Announcement Under Regulation 30 Of The SEBI LODR | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-01-31 | Disclosure under Regulation 30A of LODR | - |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-01-30 | Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended 31St December 2025 | - |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-19 | Closure of Trading Window | - |
| 2026-01-19 | Board Meeting Intimation for Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31 2025. | - |